COMPASS Pathways plc (NASDAQ:CMPS) Receives $33.60 Average PT from Analysts

Shares of COMPASS Pathways plc (NASDAQ:CMPS) have been assigned a consensus recommendation of “Buy” from the six analysts that are presently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $33.60.

A number of equities analysts have issued reports on CMPS shares. Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a report on Monday, September 9th. Royal Bank of Canada decreased their price objective on shares of COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating for the company in a report on Friday, November 1st. HC Wainwright cut their target price on shares of COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, Maxim Group decreased their price target on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 1st.

COMPASS Pathways Stock Up 1.3 %

Shares of NASDAQ CMPS opened at $3.97 on Friday. COMPASS Pathways has a 1 year low of $3.86 and a 1 year high of $12.75. The firm’s 50-day moving average is $5.03 and its 200-day moving average is $6.21. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $271.63 million, a PE ratio of -1.80 and a beta of 2.24.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.04. During the same quarter in the prior year, the firm earned ($0.67) earnings per share. Equities analysts expect that COMPASS Pathways will post -2.33 EPS for the current year.

Insider Buying and Selling

In other COMPASS Pathways news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $6.05, for a total transaction of $16,093,000.00. Following the completion of the transaction, the insider now owns 6,905,774 shares of the company’s stock, valued at $41,779,932.70. This represents a 27.81 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 4.25% of the company’s stock.

Institutional Trading of COMPASS Pathways

Hedge funds and other institutional investors have recently made changes to their positions in the business. Franklin Resources Inc. boosted its position in COMPASS Pathways by 4.4% during the third quarter. Franklin Resources Inc. now owns 295,785 shares of the company’s stock valued at $1,810,000 after purchasing an additional 12,599 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of COMPASS Pathways by 160.3% during the 3rd quarter. Geode Capital Management LLC now owns 42,169 shares of the company’s stock worth $266,000 after purchasing an additional 25,970 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of COMPASS Pathways in the 3rd quarter valued at approximately $131,000. Point72 Asset Management L.P. acquired a new stake in shares of COMPASS Pathways in the 3rd quarter valued at approximately $371,000. Finally, Polar Asset Management Partners Inc. grew its stake in shares of COMPASS Pathways by 83.3% in the third quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company’s stock valued at $3,576,000 after buying an additional 258,000 shares in the last quarter. 46.19% of the stock is currently owned by institutional investors and hedge funds.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.